Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 128
- Registration Number
- NCT04229979
- Locations
- 🇺🇸
Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States
🇫🇷CHU de Caen, Caen, France
🇬🇷General Hospital of Athens "Evaggelismos", Athens, Greece
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 333
- Registration Number
- NCT04217278
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
🇬🇧Nottingham City Hospital, Nottingham, United Kingdom
🇬🇧Manchester Royal Infirmary, Manchester, United Kingdom
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyDrug: CytarabineDrug: Daunorubicin HydrochlorideProcedure: EchocardiographyProcedure: Hematopoietic Cell TransplantationDrug: Idarubicin HydrochlorideProcedure: Multigated Acquisition ScanBiological: PembrolizumabProcedure: Punch Biopsy
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT04214249
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04195945
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 13
- Registration Number
- NCT04196010
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT04190550
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2022-03-02
- Target Recruit Count
- 172
- Registration Number
- NCT04174612
- Locations
- 🇮🇹
Aou San Luigi Gonzaga - Orbassano - Scdu Ematologia Generale E Oncoematologia, Orbassano, Italy
🇮🇹Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia, Mestre, Italy
🇮🇹Aou Policlinico P. Giaccone - Palermo - Uo Ematologia, Palermo, Italy
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT04158739
- Locations
- 🇺🇸
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
🇺🇸Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04121819
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.